NCT07427160Recruiting
Prognostic Role of Macular Neovascular Membrane Subtype in Pneumatic Displacement of Macular Hemorrhages
Source: ClinicalTrials.gov · Last updated 23 Feb 2026
Brief summary (registry, in English)
This study investigates the prognostic value of macular neovascularization (MNV) subtypes in patients treated with pneumatic displacement for submacular hemorrhage. The researchers will compare anatomical and functional outcomes (visual acuity) between PCV, RAP, and other MNV forms within a Caucasian cohort to identify subtype-specific predictors of recovery.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 17 Feb 2026
- Start date
- 15 Oct 2025
- Primary completion date
- 15 Oct 2026
- Lead sponsor
- Marco Mazzola
- Diseases
- Macular degeneration
- NCT number
- NCT07427160
What you commit to
- Study type: Observational
- Planned participants: 60
- From 15 Oct 2025 to the primary completion date, 15 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous pneumatic displacement procedures for SMH in the study eye
- Ocular surgery in the 8 weeks preceding the pneumatic displacement intervention
Other illness
- SMH secondary to conditions other than MNV
Other
- SMH estimated to be present for more than 15 days at the time of diagnosis
- Presence of proliferative diabetic retinopathy in the study eye
- Aphakia in the study eye
- Inadequate pupillary dilation, media opacities, or other impediments to retinal imaging
- Follow-up duration of less than 6 months following the procedure
Who the study is looking for
- Patients undergoing pneumatic displacement (PD) for submacular hemorrhage (SMH), secondary to macular neovascularization (MNV)
- Age 50 years or older at the time of SMH diagnosis
- Caucasian ethnicity
- SMH involving the central or internal ring of the Early Treatment Diabetic Retinopathy Study (ETDRS) grid (within a 3 mm circumference centered on the fovea)
- SMH dimensions equal to or greater than one papillary diameter
- Pneumatic displacement treatment performed within 36 hours of SMH diagnosis
Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ospedale Santa Chiara di Trento Coordinator of this site? Confirm its status | Trento | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.